Aranthan Jones II - Sep 15, 2021 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
Chief Corp. Affairs Officer
Signature
/s/ Aranthan S. Jones II
Stock symbol
VNDA
Transactions as of
Sep 15, 2021
Transactions value $
-$136,144
Form type
4
Date filed
9/17/2021, 08:52 AM
Previous filing
Jul 27, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Options Exercise $52.5K +4.28K +4.93% $12.27 91K Sep 15, 2021 Direct
transaction VNDA Common Stock Options Exercise $88.8K +7.84K +8.62% $11.32 98.8K Sep 15, 2021 Direct
transaction VNDA Common Stock Sale -$277K -16.8K -17.03% $16.49 82K Sep 15, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNDA Employee Stock Option (Right to Buy) Options Exercise $0 -4.28K -11.41% $0.00 33.2K Sep 15, 2021 Common Stock 4.28K $12.27 Direct F3
transaction VNDA Employee Stock Option (Right to Buy) Options Exercise $0 -7.84K -14.26% $0.00 47.2K Sep 15, 2021 Common Stock 7.84K $11.32 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date.
F4 The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date.